Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
12 févr. 2024 08h00 HE
|
Acasti Pharma, Inc.
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial...
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
01 févr. 2024 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
13 déc. 2023 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of...
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
13 nov. 2023 08h00 HE
|
Acasti Pharma, Inc.
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well...
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
23 oct. 2023 08h00 HE
|
Acasti Pharma, Inc.
With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million...
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
04 oct. 2023 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti Announces $7.5 Million Private Placement Equity Financing
26 sept. 2023 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti to Participate in the H.C. Wainwright Global Investment Conference
06 sept. 2023 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
11 août 2023 07h00 HE
|
Acasti Pharma, Inc.
New leadership team singularly focused on executing GTX-104 strategyAnnounced alignment with the U.S. Food and Drug Administration (FDA) for Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 with...
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting
09 août 2023 16h05 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104 its novel formulation of...